Prosecution Insights
Last updated: November 04, 2026

Vivus LLC

Technology area: Biotechnology & Pharmaceuticals

2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready

Analysis

Vivus LLC currently oversees 1 pending office action within the Biotechnology & Pharmaceuticals technology area. The company's prosecution activity is concentrated, featuring 1 distinct examiner and 1 distinct art unit. This structure indicates that the current legal efforts are focused on a specific set of claims or a specific patent application. The absence of multiple active matters suggests a focused or very early stage prosecution phase for the company's current interests.

The busiest examiner for the portfolio is SHOWALTER, ALEXANDER KEITH, who manages 1 busiest examiner pending action. This action accounts for the entirety of the company's pending workload. Consequently, the outcome of the company's current prosecution phase is tied directly to the decisions made by SHOWALTER, ALEXANDER KEITH within the identified art unit. Practitioners should prioritize understanding the specific examination patterns of this examiner, as their feedback will determine the success of the 1 pending office action before the office.

Written from this page's own data; every figure is computed from USPTO records and verified before publication.

Portfolio Summary

2
Total Pending OAs
0
Non-Final OAs
2
Final Rejections
0
Advisory / Quayle

Case Difficulty Mix

Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.

1
Hard (50%)
1
Medium (50%)
0
Easy (0%)
0
Unknown (0%)

Rejection Statute Mix

BucketCases
Double-patenting + other1 (50%)
Multi-statute (no §101)1 (50%)

Industry Mix

How the docket's pending cases split across USPTO tech-center bands.

2
Life Sciences
100% of docket
0
Information Tech
0% of docket
0
Communications
0% of docket
0
Semiconductors
0% of docket
0
Mechanical / Eng
0% of docket
0
Business / Other
0% of docket

Time-on-OA Estimate

Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.

20 h
Manual time on pending OAs
4 h
Time saved (low, 20%)
7 h
Time saved (mid, 35%)
0.2 wks
FTE-weeks freed (mid)

Top Examiners on this docket

ExaminerApps on this docketAllow rateInterview lift
BERRIOS, JENNIFER A 1 37.0% +49.7%
SHOWALTER, ALEXANDER KEITH 1 57.0% +35.4%

Hard Cases (1)

Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.

App #TitleExaminerDue in
18440516 ORALLY ADMINISTRABLE FORMULATIONS FOR THE CONTROLLED RELEASE OF A PHARMACOLOGICALLY ACTIVE AGENT BERRIOS, JENNIFER A —

Interview Candidates (2)

Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.

App #TitleExaminerDue in
18440516 ORALLY ADMINISTRABLE FORMULATIONS FOR THE CONTROLLED RELEASE OF A PHARMACOLOGICALLY ACTIVE AGENT BERRIOS, JENNIFER A —
18065437 METHOD FOR RAPID INFUSION OF CARMUSTINE SHOWALTER, ALEXANDER KEITH —

Top Art Units

Art UnitApps
1613 1
1629 1

Pending Office Actions

App #TitleExaminerArt UnitStatutesStatusDue inAIFiled
18440516 ORALLY ADMINISTRABLE FORMULATIONS FOR THE CONTROLLED RELEASE OF A PHARMACOLOGICALLY ACTIVE AGENT BERRIOS, JENNIFER A 1613 §102§103§112 Final Rejection — Pending Feb 13, 2024
18065437 METHOD FOR RAPID INFUSION OF CARMUSTINE SHOWALTER, ALEXANDER KEITH 1629 §103DP Final Rejection — Pending Dec 13, 2022

Managing Vivus LLC's Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Frequently Asked Questions

How many pending USPTO office actions does Vivus LLC have?

Vivus LLC has 2 pending office actions as of November 2026, spread across 2 art units and 2 examiners.

Which USPTO examiner handles the most Vivus LLC applications?

Jennifer A Berrios has the most, with 1 of Vivus LLC's pending office actions.

What technology area are Vivus LLC's patent applications in?

Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month